| NCT ID | NCT07605546 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jonsson Comprehensive Cancer Center |
| Condition | Cancer Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 19 participants |
| Start Date | 2026-06-09 |
| Primary Completion | 2028-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 19 participants in total. It began in 2026-06-09 with a primary completion date of 2028-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators propose to conduct a study in medically refractory cancer pain patients utilizing radiosurgery to ablate the pituitary hypophysis, as well as neuromodulate the centromedian and parafascicular complexes within the thalami - the so-called triple target. This involves treating the pituitary hypophysis and thalamus to a dose of 90 Gy. These patients will have previously failed to achieve adequate pain control with opioid pain regimens and interventional approaches. The trial will involve a multidisciplinary approach involving radiation oncology, neurosurgery, palliative care, and medical oncology colleagues across UCLA.
Eligibility Criteria
Inclusion Criteria: 1. Male or female ≥ 18 years of age on day of SRS treatment. 2. Documentation of insufficiently controlled mixed, complex cancer pain based on Brief Pain Inventory (BPI) \>8/10 despite optimization of opioid regimen 3. Not eligible for or willing to undergo further pain-relieving interventions 4. Written informed consent (and assent when applicable) obtained from patient or patient's legal representative and ability for patient to comply with the study requirements and agree to undergo the study's SRS treatment plan. Exclusion Criteria: 1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 2. Claustrophobia or inability to life flat 3. Inability to undergo routine imaging studies 4. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 5. Current history of intracranial malignancy or brain metastasis 6. Any prior intracranial irradiation 7. Previous history of craniotomy, deep brain stimulation (DBS) or laser interstitial themal therapy (LITT). 8. Presence of intracranial hardware such as leads for DBS or any other material that may interfere with safe treatment. 9. Any comorbidity or condition which would limit full compliance with the protocol
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07605546 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07605546 currently recruiting?
Yes, NCT07605546 is actively recruiting participants. Contact the research team at WDelery@mednet.ucla.edu for enrollment information.
Where is the NCT07605546 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT07605546 clinical trial?
NCT07605546 is sponsored by Jonsson Comprehensive Cancer Center. The trial plans to enroll 19 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.